Lin, C., Sajeev, G., Sung, A., Stiff, P., Brunstein, C., Cutler, C., … Horwitz, M. (2022). Abstract 8 Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study. In Stem Cells Translational Medicine (Vol. 11, pp. S10–S10). Oxford University Press (OUP). https://doi.org/10.1093/stcltm/szac057.008

Lin, Chenyu, Gautam Sajeev, Anthony Sung, Patrick Stiff, Claudio Brunstein, Corey Cutler, Guillermo Sanz, et al. “Abstract 8 Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study.” In Stem Cells Translational Medicine, 11:S10–S10. Oxford University Press (OUP), 2022. https://doi.org/10.1093/stcltm/szac057.008.

Lin C, Sajeev G, Sung A, Stiff P, Brunstein C, Cutler C, et al. Abstract 8 Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study. In: Stem Cells Translational Medicine. Oxford University Press (OUP); 2022. p. S10–S10.

Lin, Chenyu, et al. “Abstract 8 Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study.” Stem Cells Translational Medicine, vol. 11, no. Supplement_1, Oxford University Press (OUP), 2022, pp. S10–S10. Crossref, doi:10.1093/stcltm/szac057.008.

Lin C, Sajeev G, Sung A, Stiff P, Brunstein C, Cutler C, Sanz G, Lindemans C, Rezvani A, Hanna R, Koh L, Maziarz R, Hwang W, Song Y, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Horwitz M. Abstract 8 Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study. Stem Cells Translational Medicine. Oxford University Press (OUP); 2022. p. S10–S10.